SNORA71C: SNORA71C is a small nucleolar RNA (snoRNA) that belongs to the H/ACA box family [PMC6466398]. It has been found to be upregulated in glioblastoma (GBM) upon retinoic acid and/or thalidomide treatment [PMC5747948]. However, in head and neck squamous cell carcinoma (HNSCC), a different form of SNORA71C with a nucleotide mutation has been identified [PMC6466398]. SNORA71C has also been found to be upregulated in breast cancer (BC) tissues compared to normal breast tissues [PMC10106978]. Knocking down SNORA71C in BC cells resulted in decreased levels of GPX4 and PTGS2 proteins, as well as increased cell death [PMC10106978]. It has been suggested that SNORA71C promotes the proliferation, migration, and invasion of BC cells by interacting with RUNX1 [PMC10106978]. In chronic lymphocytic leukemia (CLL), SNORA71C is downregulated compared to normal B cells [PMC9219770]. Additionally, dysregulated snoRNAs, including SNORA71C, have been associated with shorter progression-free survival in CLL patients [PMC8975097]. Overall, SNORA71C is a snoRNA that plays a role in various biological processes and may serve as a potential biomarker and therapeutic target for BC treatment.